AGL 40.05 Increased By ▲ 0.02 (0.05%)
AIRLINK 134.21 Increased By ▲ 4.90 (3.79%)
BOP 6.72 Decreased By ▼ -0.08 (-1.18%)
CNERGY 4.48 Decreased By ▼ -0.16 (-3.45%)
DCL 8.81 Increased By ▲ 0.18 (2.09%)
DFML 40.86 Decreased By ▼ -0.09 (-0.22%)
DGKC 84.70 Decreased By ▼ -1.04 (-1.21%)
FCCL 32.40 Decreased By ▼ -0.60 (-1.82%)
FFBL 68.15 Increased By ▲ 1.62 (2.43%)
FFL 11.25 Decreased By ▼ -0.21 (-1.83%)
HUBC 110.45 Decreased By ▼ -0.13 (-0.12%)
HUMNL 14.35 Decreased By ▼ -0.28 (-1.91%)
KEL 5.25 Increased By ▲ 0.01 (0.19%)
KOSM 8.40 Increased By ▲ 0.29 (3.58%)
MLCF 39.49 Decreased By ▼ -0.58 (-1.45%)
NBP 60.68 Increased By ▲ 0.17 (0.28%)
OGDC 195.31 Decreased By ▼ -0.16 (-0.08%)
PAEL 26.81 Decreased By ▼ -0.29 (-1.07%)
PIBTL 7.50 Decreased By ▼ -0.14 (-1.83%)
PPL 156.00 Increased By ▲ 0.18 (0.12%)
PRL 26.70 Decreased By ▼ -0.67 (-2.45%)
PTC 18.38 Decreased By ▼ -0.18 (-0.97%)
SEARL 83.50 Decreased By ▼ -1.60 (-1.88%)
TELE 8.24 Increased By ▲ 0.34 (4.3%)
TOMCL 34.50 Decreased By ▼ -0.38 (-1.09%)
TPLP 8.91 Decreased By ▼ -0.31 (-3.36%)
TREET 16.60 Decreased By ▼ -0.21 (-1.25%)
TRG 63.89 Increased By ▲ 1.03 (1.64%)
UNITY 27.53 Decreased By ▼ -0.22 (-0.79%)
WTL 1.28 Decreased By ▼ -0.02 (-1.54%)
BR100 10,158 Decreased By -25.8 (-0.25%)
BR30 31,229 Decreased By -173.8 (-0.55%)
KSE100 95,720 Decreased By -136.7 (-0.14%)
KSE30 29,599 Decreased By -83.5 (-0.28%)

The company was incorporated in Pakistan in 1967 and is currently listed on all the stock exchanges of the country.
It is a subsidiary of a large multinational corporation engaged in the manufacturing and selling of pharmaceutical products. The registered office of the company is located at Plot-23, Korangi Industrial Area Karachi.
The share in the company is trading at Rs 270 per share which is nearly 27 times of the par value. At this market value Sanofi-Aventis Pakistan's market capitalization has shot up at Rs 2.60 bln from a small capital base of Rs 96.45 mln. For the six month ended June 30, 2006 (HY 2005-06) the company posted net sales at Rs 1.826 bln (SPLY: Rs 1.639 bln) registering 11.46% growth.
It has been clarified in the half yearly report under review that this growth is because of volume growth and sales of new products as the company has not received any price increase from the government since December 2001. However, gross profit margin has significantly improved as can be seen from the following performance statistics. The improvement shows that the company has succeeded in optimising the input cost.
Pretax profit was in the sum of Rs 184.62 mln and in this case the growth over SPLY was 32.7% which is impressive. It has been emphasized that the significantly better increase in growth rate of profit, as compared to sales growth was on account of improvement in product mix ie proportionately higher sales of products with higher gross margins, and cost controls, increase on account of inflation and sales related cost increase, is less than sales increase in percentage terms.
It has been reported that Ministry of Health recently deregistered all products containing the active ingredient Metamizol consequently the company has stopped manufacture and sale of Novalgin a product which contributed a sizeable amount of sales.



=========================================================
Performance Statistics (Mln Rs)
=========================================================
Balance sheet -As At-
=========================================================
June 30 December 31
2006 2005
=========================================================
Share Capital-Paid-up: 96.45 96.45
Reserves & Surplus: 831.21 796.69
Shareholders Equity: 927.66 893.14
L.T. Debts: - 62.50
Deferred Tax Liability: 14.03 -
Deferred Liabilities: 4.48 4.47
Current Liabilities: 998.91 1,161.10
Fixed Assets: 648.99 632.20
L.T. Loan & Advances: 11.39 11.40
L.T. Deposits: 3.32 3.30
Deferred Tax Assets: - 1.55
Current Assets: 1,281.38 1,472.76
Total Assets: 1,945.08 2,121.21
---------------------------------------------------------
Profit & Loss A/c for Half Year Ended June 30
---------------------------------------------------------
2006 2005
---------------------------------------------------------
Net-Sales: 1,826.43 1,638.58
Gross Profit: 635.07 524.10
Other Operating Income: 7.79 10.12
Operating Profit: 233.89 165.26
Finance (Cost): (49.27) (26.15)
Profit Before Taxation: 184.62 139.11
Profit After Taxation: 118.44 99.72
Earnings Per Share (Rs): 12.28 10.34
Share Price (Rs) on 04/09/06: 270.00 -
Price/Earning Ratio: 22.00 -
Book Value Per Share (Rs): 96.18 92.60
Debt/Equity Ratio: 0:100 6:94
Current Ratio: 1.29 1.27
Gross Profit Margin (%): 34.77 31.99
Net Profit Margin (%): 6.48 6.08
R.O.A. (%): 6.08 4.70
R.O.E. (%): 12.77 11.16
=========================================================

COMPANY INFORMATION: Chairman: Syed Babar Ali; Chief Executive: Tariq Wajid; Company Secretary: Not Reported; Registered Office: Plot-23, Sector 22, Korangi, Industrial Area, Karachi; Factory: Not Reported; website: Not Reported.
Copyright Business Recorder, 2006

Comments

Comments are closed.